India, March 24 -- Aditxt, Inc. (ADTX) Monday announced that its subsidiary, Pearsanta, Inc., has acquired patents related to adductomics-based DNA damage detection, strengthening its position in cancer prevention diagnostics.
The acquisition, valued at approximately $1 million, was completed through the issuance of Pearsanta Convertible Preferred Stock.
Pearsanta plans to integrate this technology into its diagnostic portfolio over the next two to three years, focusing on clinical validation, regulatory approvals, and commercialization. This aligns with its mission to advance early cancer detection using Mitomic Technology, which leverages mitochondrial DNA biomarkers for non-invasive screening. The addition of adductomics-based DNA dama...